ESMO Abstract Express: The latest progress in CT041 CAR-T treatment of gastrointestinal tumors by Keji Pharmaceutical

Shanghai, September 18, 2021/PRNewswire/ - The 2021 European Society for Medical Oncology Annual Meeting (ESMO 2021) will be held from September 16 to 21, local time

The expert who gave an oral report at ESMO this time is Dr.

The summary of the report is as follows:

Title: CLDN18.

Researchers: Qi Changsong, Qin Yanru, Liu Dan, Gong Jifang, Ge Sai, Zhang Miao, Peng Zhi, Zhou Jun, Zhang Xiaotian, Peng Xiaohui, Wang Huamao, He Chunyan, Xiao Jun, Li Zonghai, Shen Lin

Research Background:

The efficacy of CAR-T cell therapy in solid tumors is still limited

method:

CLDN18.

result:

As of April 8, 2021, a total of 37 patients with gastrointestinal tumors received CT041 infusion and completed at least 12 weeks of follow-up after the first infusion, including 28 patients with gastric cancer (GC) and 5 patients with pancreatic ductal adenocarcinoma (PDAC, pancreatic ductal adenocarcinoma) patients and 4 patients with other types of solid tumors

The overall objective response rate (ORR) for all patients and gastric cancer patients was 48.

Among 18 gastric cancer patients who had failed at least 2 previous lines of treatment and received 2.

in conclusion:

CT041 shows acceptable safety characteristics and promising anti-tumor activity in patients with refractory CLDN18.

Clinical Trials Identification: NCT03874897.

Legal entity responsible for this research: Peking University Cancer Hospital

Sponsor: Keji Biomedical (Shanghai) Co.

About CT041

CT041 is a potential first-in-class autologous CAR-T candidate product that targets CLDN18.

Up to now, CT041 is the only target CLDN18.

About Keji Pharmaceutical

Keji Pharmaceutical (stock code: 2171.

Source: Keji Biomedical